Document:

Exhibit 10.2

 

THIS WARRANT AND THE SECURITIES THAT MAY BE ACQUIRED UPON ITS EXERCISE HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES OR “BLUE SKY LAWS,”
AND MAY NOT BE OFFERED FOR SALE, SOLD, ASSIGNED, TRANSFERRED, HYPOTHECATED, OR OTHERWISE DISPOSED OF (COLLECTIVELY, A “TRANSFER”)
UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO SAID ACT AND SUCH LAWS; OR (II) THE COMPANY HAS RECEIVED
AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SAID
ACT AND SUCH LAWS AND THE RECIPIENT OF SUCH TRANSFER EXECUTES AN AGREEMENT WITH THE COMPANY (IN A FORM REASONABLY SATISFACTORY
TO THE COMPANY) OBLIGATING IT TO ABIDE BY COMPARABLE RESTRICTIONS ON TRANSFER.

 

PURSUANT TO THE TERMS OF SECTION 2(A)
OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED
BY THIS WARRANT MAY BE LESS THAN THE AMOUNT SET FORTH ON THE FACE HEREOF. 

 

SERIES J COMMON STOCK PURCHASE WARRANT

Arch
therapeutics, inc.

 

	Warrant Shares: J-_______	Initial Exercise Date: _______, 2020

 

THIS COMMON STOCK
PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________ or his or her assigns
(the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m.
(New York City time) on the one (1) year anniversary of the Initial Exercise Date (the “Termination Date”)
but not thereafter, to subscribe for and purchase from Arch Therapeutics, Inc., a Nevada corporation (the “Company”),
up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.                     Definitions.
The terms defined in the Preamble are incorporated herein.

 

Section 2.                     Exercise.

 

     

     

    

 

a)                   Exercise
of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or
times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other
office or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the
Holder appearing on the books of the Company) of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto as Exhibit A (the “Notice of
Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the
Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the
Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by
wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section
2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor
shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the
Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in
full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of
the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in
purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the
outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares
purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of
such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of
such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant
Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof. As used
herein, (A) “Trading Day” means a day on which the principal Trading Market is open for trading; and (B)
 “Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or
quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

b)                 
Exercise Price. The exercise price per share of Common Stock under this Warrant shall be $0.25, subject to adjustment
hereunder (the “Exercise Price”).

 

c)                  
[Reserved].

 

d)                 
Mechanics of Exercise.

 

    -2-

     

    

 

		i.      	Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares
                                                           purchased hereunder to be transmitted by the Transfer Agent to the Holder (1) by crediting the account of the Holder’s
                                                           or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian
                                                           system (“DWAC”) if the Company is then a participant in such system and there is an effective registration
                                                           statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder; or (2) if the
                                                           certificates are required to bear a legend regarding restriction on transferability, by issuing and dispatching by overnight
                                                           courier to the address specified in the Notice of Exercise, a certificate, registered in the Company’s share register
                                                           in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such
                                                           exercise to the address specified by the Holder in the Notice of Exercise by the date that
is the earlier of (A) the earlier of (i) two (2) Trading Days; and (ii) the number of days comprising the Standard Settlement Period,
in each case after the delivery to the Company of the Notice of Exercise; and (B) one (1) Trading Day after delivery of the aggregate
Exercise Price to the Company (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of
Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with
respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver
to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the
Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, (A) “Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise; and (B)
 “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if
the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for
such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported
by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB
or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if
prices for the Common Stock are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions
of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority
in interest of the Warrant Shares then unexercised under the Warrant and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.

 

    -3-

     

    

 

ii.            Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a
Holder and upon surrender of this Warrant, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical with this Warrant.

 

iii.           
Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.           
Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights
available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance
with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if
after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s
brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares
which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash
to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any)
for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that
the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell
order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of
the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company
timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having
a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate
sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company
shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall
limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

    -4-

     

    

 

v.            No
Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount
equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

 

vi.          
Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses
shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may
be directed by the Holder; provided, however, that in the event that Warrant Shares are to be issued in a name other
than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto
duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it
for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any
Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for same-day electronic delivery of the Warrant Shares.

 

vii.         
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

 

e)             Holder’s
Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates (such
Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the
Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to
a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any
of its Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such
calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules
required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the
determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any
Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of
the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation,
and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as
reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B)
a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company
shall within one (1) Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution
Parties since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to
the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be
effective until the 61st day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership
Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.

 

    -5-

     

    

 

Section 3.                      Certain
Adjustments.

 

a)                    Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent
securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock
issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number
of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then
in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of
Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall
be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon
exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall
remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)                 
[Reserved]

 

c)                  
Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time
the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder
could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in
the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent)
and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

d)                 
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall
be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a
record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the
Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any
shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

    -6-

     

    

 

e)                   Fundamental
Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Company with or into another Person (other than for the
purpose of changing the name or the domicile of the Company), (ii) the Company, directly or indirectly, effects any sale,
lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a
series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or
group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not
including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or
affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, at the option of the Holder, the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For
purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in
such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a
reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of
Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of
the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the
Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to
the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of
such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction,
and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into
account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is
reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead
to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of
the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been
named as the Company herein.

 

    -7-

     

    

 

f)              Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th
of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued
and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any)
issued and outstanding.

 

g)             Notice to Holder.

 

i.            
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section
3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such
adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring
such adjustment.

 

    -8-

     

    

 

ii.            Notice
to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock,
(C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or
purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall
be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is
a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange
whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it
shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the
Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or
(y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become
effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect
therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period
commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be
expressly set forth herein.

 

Section 4.               Transfer
of Warrant.

 

a)             Transferability. Neither this Warrant nor any Warrant Shares may be offered for sale, sold, transferred or assigned
unless and until (A)(i) the Holder shall have delivered to the Company (if requested by the Company) an opinion of counsel to the
Holder, in a form reasonably acceptable to the Company, to the effect that such Warrant and/or Warrant Shares to be sold, transferred
or assigned may be transferred or assigned pursuant to an exemption from registration under the Securities Act of 1933, as amended
(the “Securities Act”) and applicable state securities laws; or (ii) the Holder provides the Company with reasonable
assurance (which may include customary representation letters) that such Warrant and/or Warrant Shares can be sold, assigned or
transferred pursuant to Rule 144 promulgated under the Securities Act; and (B) the Holder shall have delivered to the Company,
in the case where any part of this Warrant is being transferred, a Series J Common Stock Purchase Warrant Assignment Form,
substantially in the form attached hereto as Exhibit B, executed by both the Holder and the transferee.

 

b)             New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be
involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant
or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant
thereto.

 

    -9-

     

    

 

c)                  
 Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

Section 6.                     Representations
and Warranties. Holder hereby represents and warrants to the Company as follows:

 

a)      
The Holder meets the requirements of at least one of the suitability standards for an “accredited investor”
as that term is defined in Regulation D as promulgated under the Securities Act.

 

b)     
The Holder is acquiring the Warrant and, as applicable, the Warrant Shares, solely for the Holder’s account for investment
purposes only and not with a view to or intent of resale or distribution thereof, in whole or in part, in violation of the Securities
Act, and the Holder has no present intention of selling, granting any participation in, or otherwise distributing the same in violation
of the Securities Act, without prejudice, however, to the Holder’s right at all times to sell or otherwise dispose of all
or any part of the Warrant and/or Warrant Shares in compliance with applicable federal and state securities laws and in compliance
with any transfer restriction to which the Warrant and the Warrant Shares may be subject at any time or from time to time.

 

c)      
The Holder has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in
securities, so as to enable it to utilize the information made available to it in connection with the Warrant to evaluate the merits
and risks of an investment in the Company and the Warrant Shares and to make an informed investment decision with respect thereto:

 

d)     
The Holder (i) understands that neither the Warrant nor the Warrant Shares issuable upon its exercise have been registered
under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the
truth and accuracy of the Holder’s representations and warranties set forth herein; and (ii) agrees not to sell, transfer
or otherwise dispose of either the Warrant or such Warrant Shares except pursuant to the terms and conditions set forth in Section
4(a) of this Warrant.

 

e)      
The Holder further understands that there can be no assurance any market will ever exist for the resale of this Warrant
or any of the Warrant Shares issuable upon the exercise of this Warrant, nor can there be any assurance that either the Warrant
or any of such Warrant Shares will be freely transferable at any time in the foreseeable future.

 

    -10-

     

    

 

Section 7.                     Registration
Rights.

 

a)                   Grant
of Right. Unless a registration statement covering the sale of this Warrant and the Warrant Shares (collectively, the
 “Registrable Securities”) by the Holder is in effect and available and subject to the provisions of Section
7(c) of this Warrant, the Holder shall have the right to include the Registrable Securities as part of any other
registration of securities filed by the Company (other than in connection with a transaction contemplated by Rule 145(a)
promulgated under the Securities Act, or pursuant to Form S-8 or any equivalent form); provided, however, that if,
solely in connection with any primary underwritten public offering for the account of the Company, the managing
underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares of Common Stock which
may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing or other factors
dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to include in
such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder
requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be
made pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable
Securities sought to be included by such Holders; provided, however, that the Company shall not exclude any
Registrable Securities unless the Company has first excluded all outstanding securities, the holders of which are not
entitled to inclusion of such securities in such Registration Statement or are not entitled to pro rata inclusion with the
Registrable Securities.

 

b)                 
Terms. The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant
to Section 7(b) hereof, but the Holder shall pay any and all underwriting commissions and the expenses of any legal counsel
selected by the Holder to represent the Holder in connection with the sale of the Registrable Securities. In the event of such
a proposed registration, the Company shall furnish the Holders of outstanding Registrable Securities with not less than thirty
(30) days written notice prior to the proposed date of filing of such registration statement. Such notice to the Holder shall continue
to be given for each registration statement filed by the Company until such time as all of the Registrable Securities have been
sold by the Holder. The holders of the Registrable Securities shall exercise the “piggy-back” rights provided
for herein by giving written notice within ten (10) days of the receipt of the Company’s notice of its intention to file
a registration statement.

 

c)                  
Termination of Registration Rights. The registration rights granted pursuant Section 7 of this Warrant shall
terminate on the Termination Date.

 

Section 8.          Miscellaneous.

 

a)      
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as
expressly set forth in Section 3.

 

    -11-

     

    

 

b)     
Restrictive Legend. Each certificate for Warrant Shares initially issued upon the exercise of this Warrant, and each
certificate for Warrant Shares issued to any subsequent transferee of any such certificate, shall be stamped or otherwise imprinted
with a legend in substantially the following form:

 

“THE
SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS
AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF SAID ACT AND SUCH LAWS. THE
SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD UNLESS (I) SUCH
SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO SAID ACT AND SUCH LAWS; OR (II) THE COMPANY HAS RECEIVED AN OPINION OF
COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER OR RESALE MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SAID
ACT AND SUCH LAWS AND THE RECIPIENT OF SUCH TRANSFER OR SALE EXECUTES AN AGREEMENT WITH THE COMPANY OBLIGATING IT TO ABIDE BY
COMPARABLE RESTRICTIONS ON TRANSFER AND RESALE.”

 

c)      
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

d)     
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

e)      
Authorized Shares.

 

The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient
number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged
with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be
listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented
by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance
herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by
the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such
issue).

 

    -12-

     

    

 

Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth
in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the
par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally
issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable
efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

 

Before taking
any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary
from any public regulatory body or bodies having jurisdiction thereof.

 

f)      
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement.

 

g)     
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal
securities laws.

 

h)     
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without
limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply
with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such
amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees,
including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise
enforcing any of its rights, powers or remedies hereunder.

 

i)       
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

 

j)       
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

    -13-

     

    

 

k)     
 Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

l)       
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

m)   
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.

 

n)     
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

o)     
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

 

(Signature Page Follows)

 

    -14-

     

    

 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	ARCH
    THERAPEUTICS, INC.	 
	 	 	 
	 	By:	            	 
	 	Name:	 
	 	Title:	 

 

     

     

    

 

EXHIBIT A

 

SERIES J COMMON STOCK PURCHASE WARRANT

NOTICE OF EXERCISE

 

To:arch
therapeutics, inc.

 

		1.	The undersigned Holder hereby irrevocably elects to exercise this Warrant and to purchase thereunder,
___________ Warrant Shares issuable upon (i) exercise of the Warrant; and (ii) delivery of $____________ (in cash, certified check,
bank draft or money order, as provided for in the foregoing Warrant) and any applicable taxes payable by the undersigned pursuant
to such Warrant. Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

		2.	The Company shall deliver to the Holder __________ Warrant Shares in accordance with the terms
of the Warrant and, after delivery of such Warrant Shares, _____________ Warrant Shares remain subject to the Warrant.

 

		3.	The undersigned Holder requests that certificates for such Warrant Shares be issued in the name
of:

 

 

(Please print name, address and social
security or federal employer identification number (if applicable))

 

		4.	The undersigned Holder hereby represents and warrants that (i) the undersigned Holder meets the
requirements of at least one of the suitability standards for an “accredited investor” as that term is defined in Regulation
D as promulgated under the Securities Act of 1933, as amended (the “Securities Act”); (ii) the undersigned Holder
is acquiring the Warrant Shares solely for the undersigned’s account for investment purposes only and not with a view to
or intent of resale or distribution thereof, in whole or in part, in violation of the Securities Act; (iii) the undersigned Holder
has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the Securities
Act, without prejudice, however, to the undersigned Holder’s right at all times to sell or otherwise dispose of all or any
part of the Warrant Shares in compliance with applicable federal and state securities laws and in compliance with any transfer
restriction to which the applicable Warrant Shares may be subject at any time or from time to time; and (iv) the undersigned Holder
has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as
to enable it to utilize the information made available to it in connection with the Warrant to evaluate the merits and risks of
an investment in the Company and the Warrant Shares and to make an informed investment decision with respect thereto.

 

[SIGNATURE
OF HOLDER]

 

	 	 	 
	 	 	 
	Name of Investing Entity:	 	 

	Signature of Authorized Signatory of Investing Entity:	 	 

	Name of Authorized Signatory:	 	 

	Title of Authorized Signatory:	 	 

	Date:	 	 

 

     

     

    

 

EXHIBIT B

 

SERIES J COMMON STOCK PURCHASE WARRANT

ASSIGNMENT FORM

 

(To assign the
foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED,
____________________ (“Assignor”) hereby sells, assigns and transfers to ___________ (“Assignee”)
all of the rights of the undersigned under the Warrant (as defined in and evidenced by the attached Warrant) to acquire ______
Warrant Shares in and to the foregoing Warrant with respect to said acquisition rights and the shares issuable upon exercise of
the Warrant (the “Warrant Shares”). This assignment agreement (the “Agreement”) is being
delivered to Arch Therapeutics, Inc., a Nevada corporation (the “Company”), pursuant to Section 4(a)
of the Warrant, and both Assignor and Assignee acknowledge and agree that the Company is an intended third party beneficiary of
this Agreement.

 

Assignee agrees that
each of the Warrant and the underlying Warrant Shares acquired by Assignee pursuant to this Agreement shall be bound by and subject
to the terms of the Warrant including, but not limited to, the transfer restrictions set forth in Section 4(a) of the Warrant,
in each case with the same force and effect as if Assignee were originally a party to the Warrant.

 

Assignee requests that
the Warrant assigned pursuant to this Agreement be issued, dated as of the Issuance Date, in the name of and delivered to:

 

 

(Please print name, address and social
security or federal employer identification number (if applicable))

 

If the total of the
Warrant Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, Assignor requests that a new Warrant dated
as of the Issuance Date and evidencing the right to acquire the Warrant Shares not so assigned pursuant to the Agreement be issued
in the name of and delivered to Assignor.

 

[SIGNATURE PAGE FOLLOWS]

 

     

     

    

 

	ASSIGNOR	 	ASSIGNEE	 
	 	 	 	 
	Print
    Name	 	Print
    Name	 
	 	 	 	 
	Signature	 	Signature	 
	 	 	 	 
	By:
    	           	 	By:
    	         	 
	Title:	 	 	Title:	 	 
	 	 	 	 
	Date	 	DateExhibit 10.3

 

THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES THAT MAY BE
ACQUIRED PURSUANT TO THIS CONVERTIBLE PROMISSORY NOTE HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933,
AS AMENDED (THE “ACT”) OR ANY STATE SECURITIES OR “BLUE SKY LAWS,” AND MAY NOT BE OFFERED FOR SALE, SOLD,
ASSIGNED, TRANSFERRED, HYPOTHECATED, OR OTHERWISE DISPOSED OF (COLLECTIVELY, A “TRANSFER”) UNLESS (I) SUCH SECURITIES
HAVE BEEN REGISTERED FOR SALE PURSUANT TO SAID ACT AND SUCH LAWS; OR (II) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY
SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SAID ACT AND SUCH LAWS AND THE RECIPIENT
OF SUCH TRANSFER EXECUTES AN AGREEMENT WITH THE COMPANY (IN A FORM REASONABLY SATISFACTORY TO THE COMPANY) OBLIGATING IT TO ABIDE
BY COMPARABLE RESTRICTIONS ON TRANSFER.

 

ARCH
THERAPEUTICS, Inc.

Series
1 UNSECURED convertible PROMISSORY NOTE

 

	$[●]	As of ________, 2020 (the “Issuance
    Date”)

 

FOR VALUE RECEIVED,
Arch Therapeutics, Inc., a Nevada corporation (“Borrower” or the “Company”)
promises to pay to [●] (“Lender”), or [his/her/its] registered assigns, in lawful money of the
United States of America (i) the principal sum of [Principal Amount] dollars ($[Principal Amount].00), or such lesser amount as
shall equal the outstanding principal amount (the “Principal Amount”) of this Series 1 Unsecured Convertible
Promissory Note, which is one of a duly authorized series of notes of the Company of like tenor and effect (except the variations
necessary to express the name of payee, the date, and the principal amount of each Note), each issued on or prior to July 3, 2020
(each a “Note” and collectively the “Notes”); and (ii) interest accrued on
the unpaid Principal Amount in accordance with Section 2. All Note Obligations (as defined below) shall be due and payable
on the earlier of (i) ON DEMAND at any time after the Maturity Date (as defined below) of this Note unless Borrower notifies
Lender that such Note Obligations will be converted into Common Stock in accordance with the terms of Section 6(c)iii);
or (ii) when, upon or after the occurrence of an Event of Default (as defined below), such amounts are declared due and payable
by Lender or made automatically due and payable in accordance with the terms hereof. Borrower and Lender may be individually referred
to herein as a “Party” or collectively as the “Parties”. On the date hereof,
in exchange for the issuance of this Note, the Lender shall pay to the Company the Principal Amount in cash via wire transfer
in accordance with the wire instructions attached hereto as Exhibit A.

 

		1.	Definitions.

 

		(a)	Preamble and Recitals: The terms defined above are incorporated herein.

 

		(b)	Other Defined Terms: For purposes of this Note, the following terms shall have the following
meanings (with terms defined in the singular having comparable meanings when used in the plural and vice versa):

 

		i)	“Borrower Optional Conversion Amount” shall
have the meaning set forth in Section 6(c)i).

 

    

     

    

 

		ii)	“Business Day” means any day other than Saturday, Sunday or a day on
which banking institutions in Massachusetts are permitted or obligated by applicable law to remain closed.

 

		iii)	“Change of Control” means any of the following: (i) the sale or disposition
of all or substantially all of the assets of Borrower to a third party; (ii) the acquisition by a third party of more than fifty
percent (50%) of Borrower’s outstanding voting capital stock; or (iii) the merger or consolidation of Borrower with or into
another entity unless the holders of Borrower’s voting capital stock immediately prior to such merger or consolidation hold
at least fifty percent (50%) of the ownership of voting capital stock of the acquiring third party or the surviving entity in such
merger or consolidation, as the case may be, immediately after the merger or consolidation. Notwithstanding the foregoing, (x)
a Change of Control shall not be deemed to occur on account of a Qualified Equity Financing; and (y) any transaction or series
of transactions principally for bona fide equity financing purposes shall not be deemed to be a Change of Control of Borrower.

 

		iv)	“Closing Date” shall have the meaning set forth in Section 6(c)i).

 

		v)	“Common Stock” means the Company’s common stock, par value $0.001
per share.

 

		vi)	“Conversion Price” shall mean $0.27 per share.

 

		vii)	“Event of Default” shall have the meaning set forth in Section 4

 

		viii)	“Fractional Payment Amount” shall have the meaning set forth in Section
6(f).

 

		ix)	“Lender Optional Conversion Amount” shall have the meaning set forth
in Section 6(b).

 

		x)	“Maturity Date” means June 30, 2020

 

		xi)	“Maximum Rate” shall have the meaning set forth in Section 2.

 

		xii)	“Note Obligations” means, as of the date of measurement, the Company’s
obligation to pay the aggregate sum of (i) the outstanding unpaid Principal Amount of this Note; (ii) all accrued and unpaid interest
thereon calculated in accordance with Section 2; and (iii) any other amounts payable hereunder with respect to this Note;
provided, however, that if Borrower notifies Lender that it will exercise its conversion right in accordance with the terms
of Section 6(c)iii), Note Obligations shall mean, for purposes of Section 6(c)iii), the aggregate sum
of (x) the product of (A) the outstanding unpaid Principal Amount of this Note as of the Maturity Date and all accrued and unpaid
interest on the outstanding unpaid Principal Amount of this Note as of the Maturity Date calculated in accordance with Section
2 and (B) 1.35; and (y) any other amounts payable hereunder with respect to this Note.

 

		xiii)	“Prepayment Date” shall have the meaning set forth in Section 6(b).

 

		xiv)	“Prepayment Notice” shall have the meaning set forth in Section 6(b).

 

    -2-

     

    

 

		xv)	“Principal Market” means the OTCQB tier of the OTC Marketplace.

 

		xvi)	“Qualified Equity Financing” means the offer and sale for cash by Borrower
of any of its equity securities with the principal purpose of raising capital that (i) results in aggregate gross proceeds to Borrower
of at least $5,000,000 (excluding any portion of the Principal Amount of any of the Notes that shall be converted into Borrower
equity securities pursuant to Section 6 of this Note, or any other convertible debt issued by the Company that are exchanged
for equity securities of the Company in such financing); and (ii) is priced at a minimum per share price of $0.27.

 

		xvii)	“Requisite Holders” means the holders of a majority of the outstanding
aggregate principal amount under the Notes.

 

		xviii)	“Securities” shall have the meaning set forth in Section 8(c).

 

		xix)	“Securities Act” means the U.S. Securities Act of 1933, as amended.

 

		xx)	“Trading Day”
means a day on which the Principal Market is open for trading.

 

		xxi)	“Trading Market” means any of the following markets or exchanges on which
the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq
Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing).

 

		xxii)	“VWAP” means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading
Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)); (b) if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable;
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported; or (d) in all other
cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the
Requisite Holders and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

		2.	Interest.
                                         Interest on the outstanding portion of the Principal Amount shall accrue at a rate equal
                                         to the lesser of ten percent (10%) per annum and the maximum non-usurious interest rate
                                         permitted by applicable law (the “Maximum Rate”). Any overdue
                                         unpaid Principal Amount shall bear interest, before and after judgment, for each day
                                         that such amounts are overdue at a rate equal to the lesser of fifteen percent (15%)
                                         per annum and the Maximum Rate. All computations of interest shall be made on the basis
                                         of a 365 day year for the actual number of days occurring in the period for which such
                                         interest is payable; provided, however, if any portion of the Principal Amount
                                         is either prepaid pursuant to Section 3 or converted pursuant to Section 6
                                         prior to the 12 month anniversary of the Issuance Date, interest accrued with respect
                                         to such prepaid or converted portion of the Principal Amount shall equal 10% of the Principal
                                         Amount that is prepaid or converted.

 

    -3-

     

    

 

		3.	Prepayment. Upon ten (10) Business Days prior written notice to Lender, Borrower may prepay
this Note in whole or in part, provided that: (i) any prepayment of this Note may only be made in connection with the prepayment
of all Notes on a pro rata basis, based on the respective aggregate outstanding Principal Amounts of each such Note; and (ii) any
such prepayment will be applied first to the payment of costs and expenses due under this Note, second to interest accrued on this
Note and third, if the amount of prepayment exceeds the amount of all such costs, expenses and accrued interest, to the payment
of the Principal Amount of this Note. Such written notice (a “Prepayment Notice”) shall specify the portion
of the Note to be prepaid, and the proposed date such prepayment shall become effective (the “PrePayment Date”).

 

		4.	Events of Default. The occurrence of any of the following shall constitute an “Event
of Default” under this Note:

 

		(a)	Failure to Pay. Borrower shall fail to pay when due any principal or interest payment on
the due date hereunder or any other amount payable hereunder when due, whether at maturity or otherwise, provided that the Company
fails to pay such amounts within 15 days of receiving written notice from the Lender that such amounts are due and unpaid; or

 

		(b)	Voluntary Bankruptcy or Insolvency Proceedings. Borrower shall (i) apply for or consent
to the appointment of a receiver, trustee, liquidator or custodian of itself or of all or a substantial part of its property; (ii)
admit in writing its inability, to pay its debts generally as they mature; (iii) make a general assignment for the benefit of its
or any of its creditors; (iv) be dissolved or liquidated; (v) commence a voluntary case or other proceeding seeking liquidation,
reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law now or
hereafter in effect or consent to any such relief or to the appointment of or taking possession of its property by any official
in an involuntary case or other proceeding commenced against it

 

		(c)	Involuntary Bankruptcy or Insolvency Proceedings. Proceedings for the appointment of a receiver,
trustee, liquidator or custodian of Borrower or of all or a substantial part of the property thereof, or an involuntary case or
other proceedings seeking liquidation, reorganization or other relief with respect to Borrower or the debts thereof under any bankruptcy,
insolvency or other similar law now or hereafter in effect shall be commenced and an order for relief entered or such proceeding
shall not be dismissed or discharged within [30] days of commencement; or

 

		(d)	Other Defaults. Borrower shall fail to pay any obligation in excess of $100,000, either
individually or in the aggregate, when the same becomes due and payable and such failure shall continue after the applicable grace
period, if any, specified in the agreement or instrument giving rise to such obligation or obligations; or

 

		(e)	Agreements. Borrower shall fail to perform or observe in all material respects any of
                                                                 its covenants or agreements in this
Note and such failure shall continue for ten (10) days after Borrower obtaining knowledge of such failure or receipt by Borrower
from Lender of a written notice of such failure.

 

    -4-

     

    

 

		5.	Rights of Lender upon Default. Upon the occurrence or existence of any Event of Default
(other than an Event of Default described in Sections 4(b) or 4(c)) and at any time thereafter during the continuance
of such Event of Default, the outstanding Note Obligations payable by Borrower hereunder shall become immediately due and payable
upon election of the Requisite Holders without presentment, demand, protest or any other notice of any kind, all of which are hereby
expressly waived. Upon the occurrence or existence of any Event of Default described in Sections 4(b) and 4(c), immediately
and without notice, all outstanding Note Obligations payable by Borrower hereunder shall automatically become immediately due and
payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived. In addition
to the foregoing remedies, upon the occurrence or existence of any Event of Default, Lender may exercise any other right power
or remedy granted to it by this Note or otherwise permitted to it by law, either by suit in equity or by action at law, or both.

 

		6.	Conversion.

 

		(a)	Automatic Conversion Upon a Change of Control. In the event that prior to a Qualified Financing
and prior to the Maturity Date, there is a Change of Control, the Note shall be converted into that number of shares of Common
Stock equal to the quotient of the Note Obligations outstanding immediately prior to the time of such Change of Control divided
by the Conversion Price. The Company shall provide the Note holders with at least five (5) days prior written notice of the anticipated
closing of a Change of Control.

 

		(b)	Lender’s Optional Conversion. Lender, in its sole discretion, may elect to have all
or any portion of the outstanding Principal Amount and all interest accrued with respect to such outstanding portion of the Principal
Amount through the date that the Lender notifies Borrower of its intent to convert pursuant to this Section 6(b) (such Principal
Amount and accrued interest, the “Lender Optional Conversion Amount”) converted into that number of shares
of Common Stock equal to the quotient of the Lender Optional Conversion Amount divided by the Conversion Price. In the event Borrower
provides Lender with a Prepayment Notice, Lender may also elect to convert all or any portion of the outstanding Principal Amount
and any interest accrued with respect to such outstanding portion of the Principal Amount in accordance with this Section 6(b)
at any time up through the Prepayment Date specified in the Prepayment Notice.

 

		(c)	Borrower’s Optional Conversion.

 

		i)	Conversion Upon a Qualified Equity Financing. Subject to the terms and conditions of this
Section 6, in the event a Qualified Equity Financing closes prior to the Maturity Date (the date of such closing, the “Closing
Date”), Borrower shall have the right, but not the obligation, to cause an amount equal to the Note Obligations outstanding
on the Closing Date to automatically convert simultaneously with the closing of the Qualified Equity Financing into that number
of shares of Common Stock equal to the quotient of the Note Obligations outstanding on the Closing Date divided by the Conversion
Price.

 

    -5-

     

    

 

		ii)	Pre-Maturity Date Conversion. In the event the VWAP of the Common Stock equals or exceeds
$0.32 per share for at least fifteen (15) consecutive Trading Days, Borrower shall have the right, but not the obligation, to have
all or any portion of the outstanding Principal Amount and all interest accrued with respect to such outstanding portion of the
Principal Amount through the date that Borrower notifies the Note holders of its intent to convert pursuant to this Section
6(c)i) (such Principal Amount and accrued interest, the “Borrower Optional Conversion Amount”) converted
into that number of shares of Common Stock equal to the quotient of the Borrower Optional Conversion Amount divided by the Conversion
Price.

 

		iii)	Maturity Date Conversion. In lieu of repaying the Note Obligations outstanding on the Maturity
Date, Borrower shall also have the right, but not the obligation, to convert all such outstanding Note Obligations into a number
of shares of Common Stock equal to the quotient of the Note Obligations outstanding on the Maturity Date divided by the Conversion
Price by providing the Note holders written notice of its intent to exercise its right to convert all outstanding Note Obligations
pursuant to this Section 6(c)iii) at least three (3) Business Days prior to the Maturity Date.

 

		iv)	Pro-Rata Application. Conversion of any Note Obligations under this Note in accordance
with this Section 6(c) may only be made in connection with the conversion of all Notes on a pro rata basis, based on the
respective aggregate outstanding Principal Amounts of each such Note.

 

		(d)	Surrender of Note. Promptly after any conversion pursuant to this Section 6, but
in no event more than five (5) Business Days thereafter, Lender shall deliver the original of this Note (or a notice to the effect
that the original Note has been lost, stolen or destroyed and an agreement acceptable to Borrower whereby the holder agrees to
indemnify Borrower from any loss incurred by it in connection with this Note arising out of any claims that the Original Note was
not lost, stolen or destroyed); provided, however, that upon Borrower’s issuance of all amounts and/or Common Stock
required under Section 6(a), Section 6(b), Section 6(c) and Section 6(f), as applicable, this Note
shall be deemed converted and of no further force and effect, whether or not it is delivered for cancellation as set forth in this
Section 6(d).

 

		(e)	Reservation of Equity Securities. Borrower covenants that all Common Stock that shall be
so issued shall be duly authorized, validly issued, fully paid, and non-assessable by Borrower, not subject to any preemptive rights,
and free from any taxes, liens, and charges with respect to the issue thereof. Borrower shall take all such action as may be necessary
to ensure that all such Common Stock may be so issued without violation of any applicable law or regulation.

 

		(f)	Fractional Securities. No fractional shares of Common Stock shall be issued upon conversion
of this Note. In lieu of Borrower issuing any fractional shares of Common Stock to Lender upon the conversion of this Note, Borrower
shall pay to Lender an amount equal to the product obtained by multiplying the Conversion Price by the fraction of a share of Common
Stock not issued pursuant to the previous sentence (the “Fractional Payment Amount”).

 

		(g)	Issuance Taxes. The issuance of Common Stock upon conversion of all or any portion of the
outstanding Note Obligations in accordance with this Section 6 shall be made without charge to Lender for any issuance tax
in respect thereof.

 

    -6-

     

    

 

		7.	Adjustments. If the Company at any time on or after the Issuance Date subdivides (by any
stock split, stock dividend, recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding
shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will
be proportionately reduced. If the Company at any time on or after the Issuance Date combines (by any stock split, stock dividend,
recapitalization, reorganization, scheme, arrangement or otherwise) one or more classes of its outstanding shares of Common Stock
into a smaller number of shares, the Conversion Price in effect immediately prior to such combination will be proportionately increased.
Any adjustment under this Section 7 shall become effective at the close of business on the date the subdivision or combination
becomes effective.

 

		8.	Representations and Warranties of Lender. Lender represents and warrants to Borrower upon
the acquisition of the Note as follows:

 

		(a)	Binding Obligation. This Note has been duly executed and delivered by Lender and is a valid
and binding obligation of Lender, enforceable against Lender in accordance with its terms, except as limited by bankruptcy, insolvency
or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general
principles of equity.

 

		(b)	Experience. Lender is
                                         an “accredited investor” as that term is defined in Rule 501 under the Securities
                                         Act. Lender has substantial experience in evaluating and investing in private placement
                                         transactions of securities in companies similar to Borrower so that Lender is capable
                                         of evaluating the merits and risks of [his/her/its] investment in Borrower and has the
                                         capacity to protect Lender’s own interests.

 

		(c)	Investment. Lender is acquiring the Note and, as applicable, the Common Stock issuable upon
conversion of the Note (collectively, the “Securities”), not as a nominee or agent, and not with the
view to, or for resale in connection with, any distribution thereof. Lender understands that the Note has not been, and that neither
the Note nor the Common Stock will be, registered under the Securities Act by reason of a specific exemption from the registration
provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of the investment
intent and the accuracy of such Lender’s representations as expressed herein and in response to Borrower’s inquiries,
if any.

 

		(d)	Rule 144. Lender acknowledges that the Securities must be held indefinitely unless subsequently
registered under the Securities Act or unless an exemption from such registration is available. Lender is aware of the provisions
of Rule 144 promulgated under the Securities Act, which permit limited resale of securities purchased in a private placement subject
to the satisfaction of certain conditions.

 

		(e)	No Active Trading Market. Lender understands that no active trading market may exist for
any of the securities issued by Borrower and that Borrower has made no assurances that either an active trading market will ever
exist for Borrower’s securities or, if one exists, that such active trading market will be maintained.

 

		(f)	Access to Data. Lender acknowledges that Lender has received all the information Lender
considers necessary or appropriate for deciding whether to acquire the Securities. Lender further represents that Lender has had
an opportunity to ask questions and receive answers from the Company regarding the
terms and conditions of the offering of the Securities.

 

    -7-

     

    

 

		(g)	Brokers or Finders. Borrower has not, and will not, incur, directly or indirectly, as a
result of any action taken by Lender, any liability for brokerage or finders’ fees or agents’ commissions or any similar
charges in connection with this Note.

 

		(h)	Tax Advisors. Lender acknowledges that it has had the opportunity to review with Lender’s
own tax advisors the federal, state, local and foreign tax consequences of this investment and the transactions contemplated by
this Note.

 

		9.	Representations and Warranties of Borrower. Borrower represents and warrants to Lender that
Borrower has full legal capacity, power and authority to execute and deliver this Note and to perform its obligations hereunder.
This Note has been duly executed and delivered by Borrower and is a valid and binding obligation of Borrower, enforceable against
it in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or
affecting the enforcement of creditors’ rights generally and general principles of equity. The execution and delivery by
Borrower of this Note and the performance of its obligations hereunder will not violate, conflict with, result in a breach of,
or constitute a default under the organizational documents or any other agreements of Borrower or any of its subsidiaries.

 

		10.	Assignment. Neither this Note nor any of the rights, interests or obligations hereunder
may be assigned by either Party, whether by operation of law or otherwise, without the other Party’s prior written consent,
and any purported attempt by a Party to assign this Note or any of the rights, interests or obligations hereunder in violation
of this Section 10 shall be null and void.

 

		11.	Transferability. No Securities may be offered for sale, sold, transferred or assigned unless
and until (i) the Note holder shall have delivered to the Company (if requested by the Company) an opinion of counsel to the Note
holder, in a form reasonably acceptable to the Company, to the effect that such Securities to be sold, transferred or assigned
may be transferred or assigned pursuant to an exemption from registration under the Securities Act and applicable state securities
laws; or (ii) the Note holder provides the Company with reasonable assurance (which may include customary representation letters)
that such Securities can be sold, assigned or transferred pursuant to Rule 144 promulgated under the Securities Act.

 

		12.	No Collateral. This Note is unsecured.

 

		13.	Notices. All notices, requests, demands, consents, instructions or other communications
required or permitted hereunder shall be in writing and emailed, mailed or delivered to each party as follows: (i) if to Lender,
at Lender’s address or email address set forth on the signature page to this Note (or at such other address or email address
as Lender shall have furnished to Borrower in writing), or (ii) if to Borrower, at the following address or email address (or at
such other address or email address as Borrower shall have furnished to Lender in writing):

 

		Borrower	

 

Arch Therapeutics,
Inc.

235 Walnut
Street, Suite 6

Framingham
MA 01702

E-mail
address: rdavis@archtherapeutics.com

Attention:
Chief Financial Officer

 

    -8-

     

    

 

All such notices
and communications will be deemed effectively given the earlier of (i) when received; (ii) when delivered personally; (iii) when
emailed (with receipt of appropriate confirmation); (iv) one Business Day after being deposited with an overnight courier service
of recognized standing; or (v) four days after being deposited in the U.S. mail, first class with postage prepaid.

 

		14.	Miscellaneous.

 

		(a)	Survival. The representations, warranties, covenants and agreements made herein shall survive
the execution and delivery of this Note.

 

		(b)	Severability. If any provision of this Note shall be judicially determined to be invalid,
illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected
or impaired thereby.

 

		(c)	Usury. In the event any interest is paid on this Note which is deemed to be in excess of
the then Maximum Rate, then that portion of the interest payment representing an amount in excess of the then Maximum Rate shall
be deemed a payment of principal and, notwithstanding Section 3, be applied against the principal of this Note.

 

		(d)	Waivers. Borrower hereby waives notice of default, presentment or demand for payment, protest
or notice of nonpayment or dishonor and all other notices or demands relative to this instrument.

 

		(e)	Costs. Each of the Parties hereto shall pay its own fees and expenses (including the fees
of any attorneys, accountants or others engaged by such Party) in connection with this Note and the transactions contemplated hereby
whether or not the transactions contemplated hereby are consummated. If Borrower shall default on
the payment of any of the Note Obligations, Borrower shall reimburse Lender on demand for its reasonable, documented out-of-pocket
costs of collection, including reasonable attorney’s fees and disbursements. 

 

		(f)	No Drafting Presumption. The language used in this Note shall be deemed to be the language
chosen by the Parties to express their mutual intent, and no rule of strict construction shall be applied against any Party.

 

		(g)	Reservation of Rights. No failure on the part of Lender to exercise, and no delay in exercising,
any right, power, privilege or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof
by Lender preclude any other or further exercise thereof or the exercise of any other right, power, privilege or remedy of Lender.

 

		(h)	CHOICE OF LAW. THIS NOTE AND ALL ACTIONS, CAUSES OF ACTION OR CLAIMS OF ANY KIND (WHETHER
AT LAW, IN EQUITY, IN CONTRACT, IN TORT OR OTHERWISE) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS NOTE, OR THE NEGOTIATION,
EXECUTION OR PERFORMANCE OF THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF MASSACHUSSETS,
INCLUDING WITHOUT LIMITATION MASSACHUSSETS LAWS RELATING TO APPLICABLE STATUTES OF LIMITATION AND BURDENS OF PROOF, AVAILABLE REMEDIES
AND APPLICABLE EVIDENTIARY PRIVILEGES.

 

    -9-

     

    

 

		(i)	WAIVER OF JURY TRIAL. THE PARTIES HERETO AGREE THAT ANY SUIT, ACTION, OR PROCEEDING,
WHETHER CLAIM OR COUNTERCLAIM, BROUGHT OR INSTITUTED BY EITHER A PARTY HERETO OR ANY SUCCESSOR OR ASSIGN ON OR WITH RESPECT TO,
ARISING IN CONNECTION WITH, OR RELATED TO THIS NOTE SHALL BE TRIED ONLY BY A COURT AND NOT BY A JURY. THE PARTIES HERETO HEREBY
EXPRESSLY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY SUCH SUIT, ACTION, OR PROCEEDING. THE PARTIES HERETO ACKNOWLEDGE AND AGREE
THAT THIS SECTION 14(i) IS A SPECIFIC AND MATERIAL ASPECT OF THIS NOTE.

 

		(j)	INTEGRATION. THIS NOTE REPRESENTS THE FINAL AGREEMENT OF THE PARTIES AND MAY NOT BE CONTRADICTED
BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN
THE PARTIES.

 

		(k)	Amendments and Waivers. Any term of this Note may be amended, modified (including, without
limitation, any extension of the Maturity Date, to change the Conversion Price) or waived upon the written consent of Borrower
and the Requisite Holders; provided however, that, any such amendment or waiver must apply to all outstanding Notes. No
such waiver or consent in any one instance shall be construed to be a continuing waiver or a waiver in any other instance unless
it expressly so provides. The Company shall promptly notify all Note holders of any such change or amendment.

 

		(l)	Counterparts. This Note be manually or electronically executed in one or more counterparts
(delivery of which may occur via facsimile or electronic transmission, including as an attachment to an electronic mail message
in “pdf” or similar format), each of which shall be deemed an original, but all of which shall together constitute
one and the same instrument.

 

[Signature
Page Follows.]

 

    -10-

     

    

 

IN WITNESS WHEREOF,
the undersigned have executed this Note as of the Issuance Date.

 

	 	ARCH
    THERAPEUTICS, Inc.
	 	 
	 	By:	              	 
	 	Name:    Terrence W. Norchi, MD
	 	Title:      President & Chief Executive
    Officer
	 	 

 

	ACCEPTED AND AGREED:	 
	 	 
	[●]	 
	 	 
	By:	                	 
	Name:	 
	Title:	 
	 	 
	Address:	 	 
	 	 
	 	 
	 	 
	Email:	  	 

 

SIGNATURE PAGE TO ARCH THERAPEUTICS, INC. SERIES
1 UNSECURED CONVERTIBLE PROMISSORY NOTE

 

    

     

    

 

EXHIBIT A

Wire Instructions 

 

	Bank:                                                                        
	Account Name:                                                        
	Routing Number:                                                    
	Account Number:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]